Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04826484 · ClinicalTrials.gov registry record · Phase 3
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
A Phase 3 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT04826484: Clinical Trial Phase 3 study, sponsored by Johns Hopkins University.
NCT04826484 is a Phase 3 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04826484, a Phase 3 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.
Interventions
- DRUG Bupivacaine Hydrochloride
- DRUG Exparel 133 miligrams per 10 milliliter injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-04-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04826484
The ClinicalTrials.gov registry entry for NCT04826484 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine Hydrochloride is the first listed.
NCT04826484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04826484 about?
NCT04826484 is a clinical study titled "Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel". This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.
What is the current status of trial NCT04826484?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2021-10-01. Estimated completion is 2023-04-26.
What interventions are being tested in trial NCT04826484?
The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), Exparel 133 miligrams per 10 milliliter injection (DRUG).
Who is sponsoring clinical trial NCT04826484?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.